AIM ImmunoTech Enters Note Purchase Agreement
I'm PortAI, I can summarize articles.
AIM ImmunoTech entered a Note Purchase Agreement with Streeterville Capital, selling a $3,301,250 Promissory Note for $2,500,000. The Note has a 10% interest rate and matures in 24 months. Mandatory prepayment terms are linked to future fundraising, with default conditions increasing interest rates. Analysts rate AIM stock as a Sell with a $1.50 target, citing poor financial performance and bearish technical indicators. AIM's stock is considered underperforming due to negative equity, cash flow issues, and valuation concerns.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments